ArticleRheumatology (Oxford, England)2026
Systemic and local autoantibody responses to extracellular matrix proteins define inflammatory phenotypes across arthropathies.
Article in Rheumatology (Oxford, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectivesAutoantibodies targeting extracellular matrix proteins are emerging as critical contributors to arthritis pathogenesis, yet their presence across different arthropathies remains incompletely characterized. This study investigated systemic and local expression of proteoglycan 4 (PRG4) and cartilage oligomeric matrix protein (COMP), alongside their corresponding autoantibodies, in healthy controls and patients with OA, RA or JIA.
methodsSerum and SF samples were analysed by ELISA from control subjects, and OA, RA and JIA patients.
resultsSerum PRG4 levels were significantly decreased in RA compared with controls and OA, while JIA patients showed elevated levels. Serum COMP was significantly elevated in OA and JIA compared with controls and RA. In SF, OA showed decreased PRG4 compared with all other groups, while COMP levels were highest in OA and controls. Anti-PRG4 autoantibodies were significantly elevated in all disease groups compared with controls in serum, with RA and JIA also showing increased elevation in SF. Anti-COMP autoantibodies were significantly increased in RA and JIA serum and elevated in all disease groups in SF compared with controls. Notably, a positive correlation between PRG4 protein and anti-PRG4 antibodies was observed specifically in OA SF, suggesting local antigen-driven immune responses.
conclusionThese findings demonstrate that autoantibodies against PRG4 and COMP are present across arthropathies with distinct patterns reflecting different pathogenic mechanisms. The detection of these autoantibodies provides mechanistic insights into disease progression and potential biomarkers for identifying differential pathway activation/inflammatory subgroups within arthropathies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.